Previous 10 | Next 10 |
home / stock / esalf / esalf news
TOKYO, Sept 26, 2019 - (JCN Newswire) - Eisai Co., Ltd. and FRONTEO, Inc. announced today that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019. The Coroban predicts inpatients' tumbling and falling risks in advance an...
In early August, Rhythm Pharmaceuticals ( RYTM ) reported results from two phase 3 trials of its drug setmelanotide in rare genetic forms of obesity. The release of the results was met with a short term rally, but the stock found itself trading back at baseline within a few sessions. Throu...
TOKYO, Sept 24, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019. The abstracts highlight updates reg...
TOKYO, Sept 20, 2019 - (JCN Newswire) - Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. has announced the manufacturing and marketing approval in Japan for the indication of improvement of wearing-off phenomenon in patients with Parkinson's disease under treatment with a drug containing levod...
Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris TOKYO, Sept 20, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that Eisai's subsidiary Eisai Pharmaceuticals India Pvt. Ltd. and Mylan N. V. subsidiary Mylan India have entered into a li...
TOKYO, Sept 19, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) associated with Alz...
TOKYO, Sept 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially ...
Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Radiation Under...
TOKYO, Sept 17, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received the 33rd "IIA Japan Chairman's Award" of the Institute of Internal Auditors - Japan. The IIA Japan was established in 1957 with the aim of contributing to the sound development of Japan's industry and econ...
Discontinuation of studies based on Data Safety Monitoring Board recommendation TOKYO, Sept 13, 2019 - (JCN Newswire) - Eisai Co., Ltd and Biogen Inc. today announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid ...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...